Back to Results

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection

Study category: Infectious Diseases

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Shelby Sullivan,  MD

Shelby Sullivan, MD

Study ID

Protocol Number: 19-2746

More information available at ClinicalTrials.gov: NCT03931941

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers